The Frank W. Fitch Monoclonal Antibody Facility at the University of Chicago provides a wide range of services focusing on the generation and production of monoclonal antibodies. Since the development of hybridoma technology more than thirty years ago, the use of monoclonal antibodies that have defined specificities has become an essential tool in the rapidly growing interdisciplinary approach to biomedical technology and research. Consequently, the generation and proper manipulation of monoclonal antibodies can be critical to the successful outcome of a particular project. Since its inception in 1995, the Facility has gained extensive experience in all areas related to the production of monoclonal antibodies from developing unique immunization schedules to customized ELISA screening of subclones. Facility personnel work closely with investigators and their staff in order to derive monoclonal antibodies specifically suited to their needs. This personal attention and interaction, together with a modest fee structure, makes using the Facility a reasonable option to the prohibitive charges of most commercial vendors. During the current funding period, the Facility has served UCCRC members by generating antibodies against a diverse array of proteins. Antibodies are utilized by investigators to assess such things as the degree of malignancy of intestinal epithelial cells, the identification of T cells subsets at various phases of the immune response, or the levels of cytokines which can confer resistance to tumor viruses. The Facility also offers large-scale production of high titer antibody supernatant using bioreactor technology, conjugation of antibodies to FITC and biotin, and the development and optimization of ELISAs. New services in the Facility include assistance in the creation of custom ELISAs to be used in the investigator's laboratory, customized fusions to obtain monoclonals for DNA analysis, subcloning of hybridomas to obtain and maintain stocks of cells that are producing antibody at maximum levels and, most recently, assistance in problem-solving the difficult task of purifying IgM antibodies. The Facility's dedicated staff and Scientific Advisor are committed to continuing to provide Cancer Research Center members and the entire University community with convenient, high-quality, and cost-effective services.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA014599-34
Application #
7843303
Study Section
Special Emphasis Panel (ZCA1)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
34
Fiscal Year
2009
Total Cost
$78,942
Indirect Cost
Name
University of Chicago
Department
Type
DUNS #
005421136
City
Chicago
State
IL
Country
United States
Zip Code
60637
Trujillo, Jonathan A; Sweis, Randy F; Bao, Riyue et al. (2018) T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res 6:990-1000
Zeng, Zongyue; Huang, Bo; Huang, Shifeng et al. (2018) The development of a sensitive fluorescent protein-based transcript reporter for high throughput screening of negative modulators of lncRNAs. Genes Dis 5:62-74
Lee, Ji-Hye; Park, Beom Seok; Han, Kang R et al. (2018) Insight Into the Interaction Between RNA Polymerase and VPg for Murine Norovirus Replication. Front Microbiol 9:1466
Cheng, Jason X; Chen, Li; Li, Yuan et al. (2018) RNA cytosine methylation and methyltransferases mediate chromatin organization and 5-azacytidine response and resistance in leukaemia. Nat Commun 9:1163
Johnson, Marianna B; Hoffmann, Joscelyn N; You, Hannah M et al. (2018) Psychosocial Stress Exposure Disrupts Mammary Gland Development. J Mammary Gland Biol Neoplasia 23:59-73
Sweis, Randy F; Zha, Yuanyuan; Pass, Lomax et al. (2018) Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer 6:24
Kathayat, Rahul S; Cao, Yang; Elvira, Pablo D et al. (2018) Active and dynamic mitochondrial S-depalmitoylation revealed by targeted fluorescent probes. Nat Commun 9:334
Liu, Jun; Eckert, Mark A; Harada, Bryan T et al. (2018) m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer. Nat Cell Biol 20:1074-1083
Bhanvadia, Raj R; VanOpstall, Calvin; Brechka, Hannah et al. (2018) MEIS1 and MEIS2 Expression and Prostate Cancer Progression: A Role For HOXB13 Binding Partners in Metastatic Disease. Clin Cancer Res 24:3668-3680
Wood, Kevin; Byron, Elizabeth; Janisch, Linda et al. (2018) Capecitabine and Celecoxib as a Promising Therapy for Thymic Neoplasms. Am J Clin Oncol 41:963-966

Showing the most recent 10 out of 668 publications